R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Medical Director - Early-Stage Clinical Development

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USAIn-person

About the Job

Requirements

  • An MD is required; oncology training is preferred.
  • At least 5 years of experience in clinical development in the pharmaceutical or biotechnology industry and/or an academic or other clinical-trial setting is required; some experience and understanding of early-phase drug development is preferred.
  • Extensive experience applying data-analysis, interpretation, and clinical-relevance principles and techniques in the pharmaceutical or biotechnology industry is required.
  • Experience independently generating trial designs, writing or amending protocols and informed consent forms, constructing appropriate case report forms, and coordinating cross-functionally is required.
  • In-depth therapeutic-area experience or expertise and relevant clinical-trial experience, or a clear ability to adapt using transferable skills, are required.
  • Strong knowledge of the medical aspects of Good Clinical Practice, International Council for Harmonisation guidelines, and applicable Food and Drug Administration, European Medicines Agency, and other regulations is required.
  • Ability to work effectively within cross-functional drug-development teams and integrate multiple perspectives into the clinical development plan is required.
  • Experience authoring regulatory briefing packages and responses to health-authority questions, and contributing to regulatory strategy and cross-functional regulatory interactions, is required.
  • Demonstrated success driving cross-functional study-level strategy, including study design, feasibility, timelines and budget projections, and protocol amendments, is required. Ability to drive discussions at internal decision-making and governance bodies is required.
  • Ability to build relationships and contribute to engagements with external key opinion leaders, including advisory boards, individual engagements, and steering committees, is required.
  • Experience engaging investigators to optimize clinical-trial conduct, including presenting at investigator meetings, or a clear ability to do so, is required.
  • Experience mentoring other clinical scientists is required; experience or clear potential as an effective line manager is also required.
  • Expertise building and maintaining relationships with internal and external stakeholders is required.
  • Strong strategic-thinking and analytical skills, including making data-driven decisions, recognizing trade-offs, and setting priorities and goals, are required.
  • Strong written and business-presentation skills are required.
  • Ability to anticipate needs and assess and manage business and organizational risks is required.

Responsibilities

  • Lead clinical-science and medical aspects of the clinical-development strategy and documentation.
  • Represent the clinical-development plan on appropriate teams, sub-teams, and forums; oversee study-site personnel training; serve as the primary program-level contact for clinical-development-plan questions; oversee medical and safety data reviews and study reporting.
  • Potentially take assignment to complex, high-priority strategic studies and perform responsibilities independently with self-directed leadership.
  • Align cross-functional efforts with scientific, regulatory, and commercial objectives while executing the clinical-development plan.
  • Lead, mentor, and contribute to a cross-functional clinical-development team.
  • Oversee clinical-trial design and execution, including site selection, patient recruitment, data management, and regulatory compliance.
  • Establish and maintain relationships with clinical investigators, regulatory agencies, and key stakeholders.
  • Gather, analyze, and interpret clinical data to provide strategic insights and inform decisions and program development.
  • Manage clinical-development timelines, resource allocation, and milestones.
  • Keep abreast of scientific advancements and regulatory trends in clinical development.
  • Potentially manage multiple direct reports.

Desired Qualifications

  • Some experience and understanding of early-phase drug development.
  • Significant contributions to clinical-development-plan conception, conduct, and delivery, including alignment with scientific governance.
  • Experience enhancing or developing core and sub-team processes, structures, systems, tools, and other resources in the pharmaceutical or biotechnology industry.
  • Led or supported clinical-development contributions to major regulatory submissions, including Investigational New Drug submissions for first-in-human studies, end-of-Phase 2 briefing books, Pediatric Investigation Plans or Pediatric Study Plans, label negotiations, Breakthrough Therapy Designation, and accelerated review.
  • Ability to present clinical-development aspects of programs to major health authorities, including the Food and Drug Administration and European Medicines Agency, by teleconference or in person; experience leading health-authority interactions.
  • Ability to establish clinical-development strategy for Clinical Trial Application and Ethics Committee submissions and responses to health-authority questions.
  • Collaborative contributions to enterprise-level strategic initiatives with internal and external partners, including clinical investigators, clinicians, scientists, key opinion leaders, and colleagues in development, research, business development, commercial, and legal groups, producing outcomes that advance strategic goals.
  • Ability to influence and inspire teams and individuals.
  • Demonstrated courage and conviction, and conflict-resolution skills.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs